Patents Assigned to California Institute for Biomedical Research
-
Patent number: 10501546Abstract: Disclosed herein are immunoglobulin fusion proteins comprising an insulin therapeutic peptide and an immunoglobulin region that targets the insulin therapeutic peptide to the liver of an individual in need thereof. Further disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject, for example, diabetes and diabetes related conditions.Type: GrantFiled: September 2, 2016Date of Patent: December 10, 2019Assignee: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Feng Wang, Matthew S. Tremblay, Travis Young, Nicole Alvarez, Yan Liu, Juanjuan Du, Peter G. Schultz
-
Publication number: 20190263882Abstract: Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.Type: ApplicationFiled: December 9, 2016Publication date: August 29, 2019Applicant: The California Institute for Biomedical ResearchInventors: Feng WANG, Yan LIU, Ying WANG, Guangsen FU, Peter G. SCHULTZ
-
Patent number: 10286078Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.Type: GrantFiled: September 12, 2014Date of Patent: May 14, 2019Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTEInventors: Weijun Shen, Peter G. Schultz, Avinash Muppidi, Insha Ahmad, Pengyu Yang
-
Patent number: 10259863Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.Type: GrantFiled: January 10, 2014Date of Patent: April 16, 2019Assignee: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Feng Wang, Yong Zhang, Peter G. Schultz
-
Patent number: 10039809Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.Type: GrantFiled: December 17, 2014Date of Patent: August 7, 2018Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTEInventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
-
Patent number: 10010589Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.Type: GrantFiled: December 17, 2014Date of Patent: July 3, 2018Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTEInventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
-
Patent number: 9981956Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.Type: GrantFiled: April 14, 2017Date of Patent: May 29, 2018Assignees: The Scripps Research Institute, The California Institute for Biomedical ResearchInventors: Luke Lairson, Michael Bollong, Peter G. Schultz, Arnab K. Chatterjee, Baiyuan Yang, Puneet Kumar, Kaveri Urkalan
-
Publication number: 20180118808Abstract: Disclosed herein are switchable chimeric receptors, switchable chimeric receptor effector cells and chimeric receptor effector cell switches. The switchable chimeric receptor-ECs are generally T cells. The chimeric receptors have non-antibody extracellular domains that recognize a chimeric receptor binding partner on the chimeric receptor-EC switch or target cell. The chimeric receptor-ECs and switches may be used for the treatment of a disease or condition in a subject in need thereof.Type: ApplicationFiled: March 28, 2016Publication date: May 3, 2018Applicant: The California Institute for Biomedical ResearchInventors: Travis YOUNG, Chanhyuk KIM, Peter G. SCHULTZ
-
Patent number: 9931379Abstract: Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.Type: GrantFiled: March 7, 2017Date of Patent: April 3, 2018Assignees: The Research Foundation for The State University of New York, California Institute for Biomedical ResearchInventors: Qing Lin, Avinash Muppidi, Weijun Shen, Huafei Zou, Peter Schultz, Yulin Tian
-
Patent number: 9663499Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.Type: GrantFiled: June 5, 2014Date of Patent: May 30, 2017Assignees: The California Institute for Biomedical Research, The Scripps Research InstituteInventors: Luke Lairson, Michael Bollong, Peter G. Schultz, Arnab K. Chatterjee, Baiyuan Yang, Puneet Kumar, Kaveri Urkalan
-
Patent number: 9656972Abstract: Described herein are compounds, compositions, and methods of their use for the treatment of cystic fibrosis.Type: GrantFiled: July 2, 2014Date of Patent: May 23, 2017Assignee: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Peter G. Schultz, Arnab K. Chatterjee, Manoj Kumar, Gustav Welzel
-
Patent number: 9644021Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.Type: GrantFiled: January 10, 2014Date of Patent: May 9, 2017Assignee: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Feng Wang, Yong Zhang, Peter G. Schultz
-
Patent number: 9624276Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.Type: GrantFiled: April 16, 2015Date of Patent: April 18, 2017Assignee: The California Institute for Biomedical ResearchInventors: Travis Young, Chanhyuk Kim, Peter G. Schultz
-
Patent number: 9452170Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.Type: GrantFiled: March 13, 2014Date of Patent: September 27, 2016Assignees: The California Institute for Biomedical Research, The Scripps Research InstituteInventors: Peter G. Schultz, Arnab K. Chatterjee, Shoutian Zhu, Joshua Payette, Hongchul Yoon, Baiyuan Yang
-
Publication number: 20160045514Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Applicant: The California Institute for Biomedical ResearchInventors: Peter G. SCHULTZ, Arnab K. CHATTERJEE, Shoutian ZHU, Joshua PAYETTE, Hongchul YOON, Baiyuan YANG
-
Publication number: 20150238631Abstract: Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.Type: ApplicationFiled: October 15, 2014Publication date: August 27, 2015Applicant: The California Institute for Biomedical ResearchInventors: Chanhyuk Kim, Travis Young, Yu Cao, Jennifer Ma, Minsoo Kim, Stephanie A. Pinkerton, Peter G. Schultz
-
Publication number: 20140271955Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicants: The Scripps Research Institute, The California Institute for Biomedical ResearchInventors: Peter G. SCHULTZ, Arnab K. CHATTERJEE, Shoutian ZHU, Joshua PAYETTE, Hongchul YOON, Baiyuan YANG